Trial Profile
Health Related Quality of Life in LCIG Patients and LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy. A Multicenter Post Marketing Observational Study for LCIG in Germany and Switzerland - BALANCE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms BALANCE
- Sponsors AbbVie
- 01 Oct 2022 Results assessing baseline characteristics on the present use of levodopa/carbidopa intestinal gel in advanced Parkinsons disease published in the Parkinsonism and Related Disorders
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 05 Mar 2019 Status changed from recruiting to active, no longer recruiting.